益生元靶向肠道微生物组治疗CKD:TarGut-CKD研究
这项非随机、开放标签、三阶段试点试验在15例CKD患者中评估低聚果糖强化菊粉(p-菊粉)对肠道微生物组及代谢产物的影响。p-菊粉显著改变肠道菌群组成,增加双歧杆菌和Anaerostipes丰度,并引起粪便、尿液和血浆代谢谱的阶段性差异。结果提示p-菊粉可扩展微生物组与宿主共代谢,为基于微生物组的干预试验设计提供依据。
要点
- p-菊粉可显著改变CKD患者肠道菌群组成,增加双歧杆菌和Anaerostipes丰度。
- 尿液和粪便代谢谱在研究的三个阶段间存在显著差异,特定代谢物FDR≤0.1。
- 个体间微生物组和代谢组变异大于个体内变异,提示各阶段内微生物组稳定。
核心结论
- p-菊粉可扩展CKD患者肠道微生物组与宿主共代谢,并改变菌群组成和代谢谱。
研究设计与样本
- 非随机、开放标签、三阶段试点试验,每阶段内重复测量,纳入15例CKD患者。
- 研究包括8周预处理期、12周p-菊粉治疗期和8周治疗后期的微生物组与代谢组稳定性观察。
主要发现
- 参与者完成373/420次预期访视(88.8%),p-菊粉依从性为83.4%。
- 对368份粪便样本进行16S rRNA测序,对1085份粪便、尿液和血浆样本进行非靶向代谢组学研究。
- p-菊粉给药显著改变肠道菌群组成,增加双歧杆菌和Anaerostipes丰度。
- 尿液和粪便代谢谱的beta多样性在研究阶段间整体显著不同,多个特定代谢物在阶段间FDR≤0.1。
- 来源于糖分解的微生物代谢物显著富集。
临床怎么用
- p-菊粉有望作为CKD患者靶向肠道微生物组的干预手段,但需进一步随机对照试验验证。
- 本研究结果可为设计严格的基于微生物组的干预试验提供参考。
局限性
- 非随机、开放标签设计,样本量小(15例),可能影响因果推断。
- 缺乏对照组,无法排除时间效应等混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Disruption of gut microbiota underpins some of the metabolic alterations observed in chronic kidney disease (CKD). METHODS: In a nonrandomized, open-label, 3-phase pilot trial, with repeated measures within each phase, we examined the efficacy of oligofructose-enriched inulin (p-inulin) in changing the gut microbiome and their metabolic products in 15 patients with CKD. The stability of microbiome and metabolome was studied during the pretreatment phase (8 weeks), a p-inulin treatment phase (12 weeks), and a post treatment phase (8 weeks) of the study. RESULTS: Study participants completed 373 of the 420 expected study visits (88.8%). Adherence to p-inulin was 83.4%. 16S rRNA sequencing was performed in 368 stool samples. A total of 1085 stool, urine, and plasma samples were subjected to untargeted metabolomic studies. p-inulin administration altered the composition of the gut microbiota significantly, with an increase in abundance of Bifidobacterium and Anaerostipes. Intersubject variations in microbiome and metabolome were larger than intrasubject variation, indicating the stability of the gut microbiome within each phase of the study. Overall metabolite compositions assessed by beta diversity in urine and stool metabolic profiles were significantly different across study phases. Several specific metabolites in stool, urine, and plasma were significant at false discovery rate (FDR) ≤ 0.1 over phase. Specifically, there was significant enrichment in microbial metabolites derived from saccharolysis. CONCLUSION: Results from our study highlight the stability of the gut microbiome and the expansive effect of p-inulin on microbiome and host cometabolism in patients with CKD. Findings from this study will enable rigorous design of microbiome-based intervention trials.
引用
- Sohn MB, Gao B, Kendrick C, et al. Targeting Gut Microbiome With Prebiotic in Patients With CKD: The TarGut-CKD Study. Kidney Int Rep. 2023. PMID: 38481512. doi:10.1016/j.ekir.2023.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。